183 related articles for article (PubMed ID: 35721889)
21. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
[TBL] [Abstract][Full Text] [Related]
22. The potential of gut microbiome as a non-invasive predictive biomarker for early detection of pancreatic cancer and hepatocellular carcinoma.
Kaźmierczak-Siedlecka K; Stachowska E; Folwarski M; Przewłócka K; Makarewicz W; Bryl E
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7275-7284. PubMed ID: 34919227
[TBL] [Abstract][Full Text] [Related]
23. The Microbiome and Liver Cancer.
Myojin Y; Greten TF
Cancer J; 2023 Mar-Apr 01; 29(2):57-60. PubMed ID: 36957974
[TBL] [Abstract][Full Text] [Related]
24. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
26. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
Zhang CH; Li M; Lin YP; Gao Q
Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab for the treatment of hepatocellular carcinoma.
Finkelmeier F; Waidmann O; Trojan J
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in hepatocellular cancer.
Fountzilas C; Evans R; Alaklabi S; Iyer R
Adv Cancer Res; 2021; 149():295-320. PubMed ID: 33579426
[TBL] [Abstract][Full Text] [Related]
29. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
Mazzolini GD; Malvicini M
Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
[TBL] [Abstract][Full Text] [Related]
30. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
[TBL] [Abstract][Full Text] [Related]
32. The Gut Microbiome and Hepatocellular Carcinoma.
Akkız H
J Gastrointest Cancer; 2021 Dec; 52(4):1314-1319. PubMed ID: 34870783
[TBL] [Abstract][Full Text] [Related]
33. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
[TBL] [Abstract][Full Text] [Related]
34. Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors.
Nomura M; Nagatomo R; Doi K; Shimizu J; Baba K; Saito T; Matsumoto S; Inoue K; Muto M
JAMA Netw Open; 2020 Apr; 3(4):e202895. PubMed ID: 32297948
[TBL] [Abstract][Full Text] [Related]
35. Combining systemic and local therapies for hepatocellular carcinoma.
Wehrenberg-Klee E; Goyal L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):976-978. PubMed ID: 34695376
[No Abstract] [Full Text] [Related]
36. Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy.
De Somer T; Vanderstraeten E; Bouderez V; Monsaert E; Van Steenkiste C
Acta Clin Belg; 2022 Feb; 77(1):108-112. PubMed ID: 32529925
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy in older patients with hepatocellular carcinoma.
Lyu N; Yi JZ; Zhao M
Eur J Cancer; 2022 Feb; 162():76-98. PubMed ID: 34954439
[TBL] [Abstract][Full Text] [Related]
38. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma.
Wu H; Zheng X; Pan T; Yang X; Chen X; Zhang B; Peng L; Xie C
Int J Cancer; 2022 Oct; 151(8):1321-1334. PubMed ID: 35579980
[TBL] [Abstract][Full Text] [Related]
39. The Microbiome and Hepatocellular Carcinoma.
Rattan P; Minacapelli CD; Rustgi V
Liver Transpl; 2020 Oct; 26(10):1316-1327. PubMed ID: 32564483
[TBL] [Abstract][Full Text] [Related]
40. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice.
Rimola J; Da Fonseca LG; Sapena V; Perelló C; Guerrero A; Simó MT; Pons M; De La Torre-Aláez M; Márquez L; Calleja JL; Lledó JL; Varela M; Mínguez B; Sangro B; Matilla A; Torres F; Ayuso C; Bruix J; Reig M
Eur J Radiol; 2021 Feb; 135():109484. PubMed ID: 33383399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
